Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Diuretic Treatment in Acute Heart Failure Guided by Serial Spot Urine Sodium
2021-005426-18Phase 4Completed
- Sponsor
- UZ Brussel
- Start
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of bumetanide, spironolactone, potassium canrenoate, acetazolamide and chlorthalidone in Acute Heart Failure (AHF), sponsored by UZ Brussel. Primary endpoint: Hierarchical win ratio endpoint for decongestion and clinical outcomes. Started Oct 2021; status: completed.
02
Drugs
bumetanidespironolactonepotassium canrenoateacetazolamidechlorthalidone
03
Conditions
Acute Heart Failure (AHF)
Beyond the preview
Go deeper on 2021-005426-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-005426-18.